advertisement
Oncology and Hematology
516
145-160 of 226
- MinuteCE®
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
1.50 program credits
Erica L. Mayer, MD, MPH
Peter Schmid, FRCP, MD, PhD
William J. Gradishar, MD
Sara Lonardi, MD
Aparna R. Parikh, MD
Alan Venook, MD
Erica L. Mayer, MD, MPH
Aparna R. Parikh, MD
William J. Gradishar, MD
Alan Venook, MD
Nicoletta Colombo, MD
Susana Campos, MD, MPH
Ritu Salani, MD
Ignacio Duran, MD
Wenxin Xu, MD
Sandy Srinivas, MD
- MinuteCE®
First-Line Maintenance Therapy Using PARP Inhibitors for Ovarian Cancer
1.00 program creditNicoletta Colombo, MD
Ritu Salani, MD
- MinuteCE®
Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer
1.00 program creditRitu Salani, MD
Nicoletta Colombo, MD
Ignacio Duran, MD
Wenxin Xu, MD
